Myriad Genetics Q3 Revenue Beats Estimates, Raises FY Guidance

Myriad Genetics, Inc. released its financial results for the third quarter of 2026, reporting progress in its strategy to accelerate profitable growth and improve its financial profile. Alongside the quarterly results, the company announced an increase to the mid-point of its revenue guidance for the full 2026 fiscal year. Management attributed the performance to strong execution and operational progress. The company continues to focus on its core molecular diagnostic testing and precision medicine business.